Drugs / Balugrastim
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01940601 | Sep 2014 → Nov 2015 | cancer | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00837265 | Aug 2008 → Jun 2009 | neutropenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01126190 | Jun 2010 → Feb 2012 | neutropenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Balugrastim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01940601 ↗ |
| Known as | CG-10639 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108572 ↗ |
| Known as | Neugranin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01126190 ↗ |
| Action | Activate | “Granulocyte colony stimulating factor receptor agonist” CHEMBL2108572 ↗ |
| Modality | Protein / enzyme biologic | “Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.” NCT00837265 ↗ |
| Route | Subcutaneous | “Participants will receive balugrastim low dose administered by subcutaneous (SC) injection once per chemotherapy cycle” NCT00837265 ↗ |
| Target | CSF3R | “Granulocyte colony stimulating factor receptor agonist” CHEMBL2108572 ↗ |